Patent Board Sides With Patent Owner In Final Written Decision
ALEXANDRIA, Va. — A patented method for treating inflammatory autoimmune diseases with a high concentration subcutaneous methotrexate formulation was confirmed as patentable on Feb. 7 by the Patent Trial and Appeal...To view the full article, register now.
Already a subscriber? Click here to view full article